2014年临床肿瘤学新进展学术研讨会――BestofASCOEventin.DOC

2014年临床肿瘤学新进展学术研讨会―― Best of ASCO? Event in China 2014 会议日程Program 会议第一天 2014年7月11日 (Day 1, July 11, 2014) 8:00–8:1 开幕式 (Opening eremony) CSCO代表吴一龙教授 致辞 (Opening speech by Prof. YiLong Wu on behalf of CSCO) ASCO代表Peter Yu教授 致辞 (Opening speech by Prof. Peter Yu on behalf of ASCO) 血液肿瘤专场 (Hematologic alignancy) 主席(Chair)：时间(Time) 题目(Topic) 讲者(Speaker) 8:1–8:40 Abstract 7005^ Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL). BiTE antibody blinatumomab在复发/难治性急性前体B淋巴细胞白血病患者（r/ r ALL）的验证性多中心、开放标签的单臂2期研究。 糜坚青(Jian-Qing Mi) Abstract 7008 Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial. ibrutinib与ofatumumab在复发或难治性（R/R）慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的随机比较：来自RESONATE Ⅲ期试验的结果。 Abstract 7026 Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial. Ruxolitinib（RUX）在羟基脲耐药或不能耐受的真性红细胞增多症（PV）患者的前瞻性、随机、开放标签的Ⅲ期研究结果：RESPONSE试验。 8:40–8:50 专家评述 Discussion Topic: A comprehensive overview on molecular targeted therapy for leukemia 讨论主题： 8:50–8:55 讨论(Q A) (Jian-Min Wang) 李建勇(Jian-Yong Li) 泌尿系统肿瘤专场1 (Genitourinary Cancer Session 1) 主席(Chair) 时间(Time) 题目(Topic) 讲者(Speaker) 8:55–9: Abstract LBA2 Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. 一项ECOG领导的 III期随机临床试验：激素敏感的新发转移性前列腺癌患者（mPrCa）接受化疗联合内分泌治疗对比单用内分泌治疗对于总生存期(OS)的影响。 戴 波(Bo Dai) Abstract 5003 Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. PSA复发的前列腺癌患者接受立即雄激素剥夺治疗与延迟雄激素剥夺治疗的比较。 Abstract 5008 Phase 3, randomized, placebo-